Ftse Mib
34.355,05
0,12%
DAX
20.277,03
0,12%
S&P 500
6.050,61
0,00%
NASDAQ
20.109,06
0,00%
Bitcoin
104.942,55
-1,14%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Karyopharm Therapeutics Inc (KPTI) Karyopharm Therapeutics Inc (KPTI) Notizie

KPTI

Karyopharm Therapeutics (KPTI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KPTI
DataOraFonteTitoloSimboloCompagnia
16/12/202422:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
09/12/202414:00PR Newswire (US)Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate CommunicationsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202422:35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KPTIKaryopharm Therapeutics Inc
05/12/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/12/202413:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
03/12/202413:00PR Newswire (US)Karyopharm Therapeutics Provides Endometrial Cancer Program UpdateNASDAQ:KPTIKaryopharm Therapeutics Inc
02/12/202413:00PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
25/11/202413:00PR Newswire (US)Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
22/11/202422:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
20/11/202422:05PR Newswire (US)Karyopharm Therapeutics Announces the Appointment of Chief Accounting OfficerNASDAQ:KPTIKaryopharm Therapeutics Inc
14/11/202422:22Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202414:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202413:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
05/11/202413:30PR Newswire (US)Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202413:00PR Newswire (US)Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
31/10/202412:30PR Newswire (US)Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202421:30PR Newswire (US)Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
03/09/202413:00PR Newswire (US)Karyopharm to Participate at Upcoming Investor ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/08/202413:30PR Newswire (US)Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
31/07/202422:05PR Newswire (US)Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
19/07/202422:07Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
20/06/202414:01Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:KPTIKaryopharm Therapeutics Inc
10/06/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KPTIKaryopharm Therapeutics Inc
01/06/202419:45PR Newswire (US)Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesNASDAQ:KPTIKaryopharm Therapeutics Inc
30/05/202422:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KPTIKaryopharm Therapeutics Inc
29/05/202422:05PR Newswire (US)Karyopharm to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
23/05/202422:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202422:05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413:30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413:30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KPTI

La tua Cronologia

LATK
AGAINETH
AGAIN
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network